Corporate Focus On the second day of the 2026 J.P. Morgan Healthcare Conference, Stefan Oelrich, President of Bayer’s Pharmaceuticals Division, outlined the group’s comprehensive transformation. Following a period of patent expirations for key legacy products, Bayer is now prioritizing operational efficiency and new growth catalysts.
Strategic Highlights:
-
Momentum from New Launches: New product launches contributed $1.7 billion in revenue during the first nine months of 2025. The group anticipates 2026 to be the final transitional year before entering a phase of mid-single-digit revenue growth starting in 2027.
-
Five Key Growth Pillars:
-
Nubeqa: A prostate cancer treatment poised to become a market leader with the company’s highest revenue potential.
-
Kerendia: A pioneering solution in cardiovascular and renal care.
-
Lynkuet (elinzanetant): A non-hormonal therapy for menopause, targeting a high-unmet-need market segment.
-
Asundexian: A next-generation anticoagulant expected to redefine standards of care with superior safety profiles.
-
U.S. Market Re-entry: Focusing on strategic cardiovascular assets to rebuild its North American footprint.
-
-
Operational Streamlining: Through the “Dynamic Shared Ownership” (DSO) model, Bayer has reduced its workforce by over 12,000 positions (primarily in management) to eliminate bureaucracy, aiming for €2 billion in annual savings by the end of 2026.
-
Financial Outlook: Bayer targets a return to profit margins in the 30% range by 2030, while simultaneously working to resolve long-standing legal challenges and litigation issues.
Source: https://www.pharmexec.com/view/jp-morgan-2026-bayer-rejuvenated-portfolio